Jessie R Davis
Overview
Explore the profile of Jessie R Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
2463
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Author Correction: In vivo base editing extends lifespan of a humanized mouse model of prion disease
An M, Davis J, Levy J, Serack F, Harvey J, Brauer P, et al.
Nat Med
. 2025 Jan;
PMID: 39885360
No abstract available.
2.
An M, Davis J, Levy J, Serack F, Harvey J, Brauer P, et al.
Nat Med
. 2025 Jan;
PMID: 39810005
Prion disease is a fatal neurodegenerative disease caused by the misfolding of prion protein (PrP) encoded by the PRNP gene. While there is currently no cure for the disease, depleting...
3.
An M, Raguram A, Du S, Banskota S, Davis J, Newby G, et al.
Nat Biotechnol
. 2024 Jan;
42(10):1526-1537.
PMID: 38191664
Prime editing enables precise installation of genomic substitutions, insertions and deletions in living systems. Efficient in vitro and in vivo delivery of prime editing components, however, remains a challenge. Here...
4.
Doman J, Pandey S, Neugebauer M, An M, Davis J, Randolph P, et al.
Cell
. 2023 Sep;
186(18):3983-4002.e26.
PMID: 37657419
Prime editing enables a wide variety of precise genome edits in living cells. Here we use protein evolution and engineering to generate prime editors with reduced size and improved efficiency....
5.
Ely Z, Mathey-Andrews N, Naranjo S, Gould S, Mercer K, Newby G, et al.
Nat Biotechnol
. 2023 May;
42(3):424-436.
PMID: 37169967
Genetically engineered mouse models only capture a small fraction of the genetic lesions that drive human cancer. Current CRISPR-Cas9 models can expand this fraction but are limited by their reliance...
6.
Davis J, Banskota S, Levy J, Newby G, Wang X, Anzalone A, et al.
Nat Biotechnol
. 2023 May;
42(2):253-264.
PMID: 37142705
Realizing the promise of prime editing for the study and treatment of genetic disorders requires efficient methods for delivering prime editors (PEs) in vivo. Here we describe the identification of...
7.
Everette K, Newby G, Levine R, Mayberry K, Jang Y, Mayuranathan T, et al.
Nat Biomed Eng
. 2023 Apr;
7(5):616-628.
PMID: 37069266
Sickle-cell disease (SCD) is caused by an A·T-to-T·A transversion mutation in the β-globin gene (HBB). Here we show that prime editing can correct the SCD allele (HBB) to wild type...
8.
Sreekanth V, Jan M, Zhao K, Lim D, Davis J, McConkey M, et al.
bioRxiv
. 2023 Mar;
PMID: 36945568
Cas9 is a programmable nuclease that has furnished transformative technologies, including base editors and transcription modulators (e.g., CRISPRi/a), but several applications of these technologies, including therapeutics, mandatorily require precision control...
9.
Davis J, Wang X, Witte I, Huang T, Levy J, Raguram A, et al.
Nat Biomed Eng
. 2022 Aug;
6(11):1317.
PMID: 35931809
No abstract available.
10.
Davis J, Wang X, Witte I, Huang T, Levy J, Raguram A, et al.
Nat Biomed Eng
. 2022 Jul;
6(11):1272-1283.
PMID: 35902773
The viral delivery of base editors has been complicated by their size and by the limited packaging capacity of adeno-associated viruses (AAVs). Typically, dual-AAV approaches based on trans-splicing inteins have...